The 20th anniversary of the MSF Access Campaign
Andrea Bussotti & Jean-Hervé Bradol
Operational Communications Manager MSF-OCP.
Medical doctor, specialized in tropical medicine, emergency medicine and epidemiology. In 1989 he went on mission with Médecins sans Frontières for the first time, and undertook long-term missions in Uganda, Somalia and Thailand. He returned to the Paris headquarters in 1994 as a programs director. Between 1996 and 1998, he served as the director of communications, and later as director of operations until May 2000 when he was elected president of the French section of Médecins sans Frontières. He was re-elected in May 2003 and in May 2006. From 2000 to 2008, he was a member of the International Council of MSF and a member of the Board of MSF USA. He is the co-editor of "Medical innovations in humanitarian situations" (MSF, 2009) and Humanitarian Aid, Genocide and Mass Killings: Médecins Sans Frontiéres, The Rwandan Experience, 1982–97 (Manchester University Press, 2017).
To address the political, economic and legal barriers to patients' access to life-saving treatments, MSF created, in 1999, the Access Campaign (the Campaign for Access to Essential Medicines). In this video, Jean-Hervé Bradol, doctor and Crash study director, answers questions from Andrea Bussotti (MSF-France Operational Communication Manager). In the light of the historical background of the early days of the Access Campaign, he analyses the medico-operational context of the Campaign today and asks himself the question of its objectives.
Video
Doing Drugs – Video briefing on access to medicines
02/03/2022On 3rd and 4th February 2022, the CRASH organised a workshop aimed at the leaders, operational managers and members of MSF France, to shed light on the current debates on access to medicines, and to determine together which issues are the most relevant to resolve. In preparation for this workshop, the CRASH asked experts external to MSF to explain their vision of today’s pharmaceutical industry system, with subjects that ranged from pre-development to distribution, and included patents and quality-related issues.